2018 Innovation to Commercialization award recipients

The Innovation to Commercialization (I2C) Program is designed to help researchers advance discoveries or inventions towards commercialization by supporting commercialization activities that strengthen the value of their intellectual property, facilitate collaboration and attract future investment.

Now in its second year, MSFHR is pleased to announce eight successful award recipients. Working at six BC institutions, these individuals are advancing health innovations that range from new ways to detect prostate cancer, to a novel treatment for inflammatory bowel disease and a wearable exoskeleton to increase the mobility of people with lower limb disabilities.

(Host institution)
Project summary Research location
Siamak Arzanpour
Developing an advanced wearable exoskeleton to increase the mobility of people with lower limb disabilities
*Co-funded with the Rick Hansen Institute
SFU (Surrey)
Jaimie Borisoff
Refining an exercise machine that allows walking-like leg movements to improve cardiovascular fitness in people with lower limb disabilities BCIT
Robert Hancock
Developing a topical intranasal treatment for chronic inflammation of the nasal sinuses UBC
Dirk Lange
Producing and testing catheters with a unique coating that prevents bacterial attachment and has the potential to limit catheter-related infections VCHRI
Megan Levings
Developing a novel treatment for Inflammatory Bowel Disease to treat intestinal inflammation without affecting the rest of the immune system BCHRI
Jessica McAlpine
BC Cancer
Adapting a lab-based tool for endometrial cancer classification to inform treatment decisions for women with endometrial cancer across Canada BC Cancer
David Perrin
Developing better diagnostic agents for prostate cancer to allow tumours to be detected earlier and more effectively UBC
Marinko Sarunic
Developing a diagnosis and treatment tool for irreversible vision loss caused by age-related macular degeneration and diabetic retinopathy SFU (Burnaby)